Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
Journal: Journal of the American Academy of Dermatology
Published: June 27, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study.
Journal: Journal of the American Academy of Dermatology
Published: December 20, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design.
Journal: Clinical and translational science
Published: March 11, 2024
Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: December 19, 2022
Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials.
Journal: Aesthetic surgery journal
Published: September 10, 2022
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
Journal: Drugs
Published: October 13, 2021
A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: August 11, 2020
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: August 11, 2020
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
Journal: Journal of the American Academy of Dermatology
Published: January 23, 2019
Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: December 01, 2017
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study.
Journal: Movement disorders clinical practice
Published: November 30, 2017
Last Updated: 09/26/2026